A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancerKimberly Blackwell, M. S. Berger, Eli Kaplan et al.|Journal of Clinical Oncology|2004Cited by 90
A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancerKim T. Blackwell, M. S. Berger, Eli Kaplan et al.|Journal of Clinical Oncology|2004Cited by 44
Investigation of tumor biomarkers as response predictors in a monotherapy study with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cancerHenry Gómez, Adrián Martín, S. Stein et al.|Journal of Clinical Oncology|2007Cited by 11
PCN358 DEMOGRAPHIC, CLINICAL CHARACTERISTICS, TREATMENT PATTERNS AND CLINICAL OUTCOMES BY LINES OF TREATMENT IN HR+/HER2− ADVANCED BREAST CANCER IN COLOMBIASandra Franco, J.M. Reyes Sanchez, Brigitte Alejandra Alarcon et al.|Value in Health|2020Cited by 0